In conclusion, although differing in molecular mechanisms, EPO exerts anti-inflammatory and metabolic actions in key insulin-sensitive tissues, positioning it as a compelling target in obesity-associated metabolic disorders. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.